Years of lax regulations helped India build a booming market for clinical trials, but a recent move to strengthen patient protections has deflated demand and last year saw just 19 studies get underway in the country, according to The Pharma Letter.
Generic drug maker Actavis is unloading some of its manufacturing assets as it digests the big chunk of business it bit off with its Warner Chilcott merger last year. It has reached a deal to unload its piece of a manufacturing plant in China after last week deciding to sell 7 money-losing API plants in Europe.
Years of lax regulations helped India build a booming market for clinical trials, but a recent move to strengthen patient protections has deflated demand, and last year saw just 19 studies get underway in the country, The Pharma Letter reports.
ResearchDx, one of the few outfits devoted to contract test making, has extended its operation to include the Middle East, a region the company said is home to a growing biotech market.
Covidien's efforts to move its device business overseas continue as the Irish company opened a medical training and education center in Mumbai, India.
Varian Medical Systems reported yesterday that revenues during its first fiscal quarter jumped 5% from the same period a year ago to $712 million, and net income rose 3% to $98 million. The company cited particularly strong demand for its oncology products, which include equipment for performing radiosurgery and software that physicians can use in treatment planning.
In 2002 India suffered 1,599 cases of polio, 17 times more than Pakistan experienced that year. Yet a little more than one decade later India has eradicated polio, while a city in Pakistan is being called the world's "largest reservoir" of the virus.
Animal model specialist Harlan Laboratories is moving to expand its share of the Indian research market, planning to open its first breeding facility in the country.
Actavis CEO Paul Bisaro says the company has sold a China unit and is in talks to unload another, telling Bloomberg he has decided to retreat from a country that isn't worth all of the effort it requires.
Ask Actavis CEO Paul Bisaro about China and he'll tell you this: It's more trouble than it's worth. As Bloomberg reports, the generics maker is backing away from the Chinese market, despite forecasts of long-term drug-spending growth there.